Home › Endometrial Cancer › Maryland
Endometrial Cancer clinical trials in Maryland
22 studies for Endometrial Cancer are looking for participants at sites in Maryland.
Cities in Maryland
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Walter Reed National Military Medical Center, Bethesda
- National Institutes of Health Clinical Center, Bethesda
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Oct 2, 2026 · NCT01174121A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06172478A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Sinai Hospital, Baltimore
- William Kahlert Reg. Can. Ctr, Westminster
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Baltimore
- Research Site, Silver Spring
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- National Institutes of Health, Bethesda
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Maryland Oncology Hematology - Primary, Columbia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT04657068Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Baltimore
- Research Site, Baltimore
- Research Site, Silver Spring
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Integrated Cancer Repository for Cancer Research
- Northwest Hospital, Randallstown
- William E. Kahlert Regional Cancer Center, Westminster
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07327489Vaginal Cuff Brachytherapy Fractionation Study
- University of Maryland Medical Center (UMMC), Baltimore
RecruitingPhase 3
Ages 18 and older · Women · Updated Apr 22, 2026 · NCT03785288Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Apr 9, 2026 · NCT06253494Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT03968406Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Brandywine
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 24, 2025 · NCT06463028A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Baltimore
- Massive Bio SYNERGY-AI site, Bethesda
- Massive Bio SYNERGY-AI site, Silver Spring
- and 1 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774BP1001-A in Patients With Advanced or Recurrent Solid Tumors
- Holy Cross Hospital, Silver Spring
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 7, 2025 · NCT04196257Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- Maryland Oncology Hematology, P.A., Silver Spring
RecruitingPhase 2/3
Ages 18 and older · Women · Updated May 2, 2024 · NCT05797831From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.